XPP:ARCA-ProShares Ultra FTSE China 50 (USD)

ETF | Trading--Leveraged Equity | NYSE Arca

Last Closing

USD 19.12

Change

+0.36 (+1.91)%

Market Cap

USD 0.04B

Volume

4.73K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the FTSE China 50 Index?. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index consists of 50 of the largest and most liquid Chinese stocks listed and traded on the Stock Exchange of Hong Kong. The fund is non-diversified.

Inception Date: 04/06/2009

Primary Benchmark: FTSE China 50 USD TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.3%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Trading--Leveraged Equity

Symbol Name Mer Price(Change) Market Cap
SOXL Direxion Daily Semiconductor B.. 1.10 %

N/A

USD 9.92B
FNGU MicroSectors FANG+ Index 3X Le.. 0.00 %

N/A

USD 7.96B
QLD ProShares Ultra QQQ 0.95 %

N/A

USD 7.84B
SSO ProShares Ultra S&P500 0.90 %

N/A

USD 5.60B
UPRO ProShares UltraPro S&P500 0.92 %

N/A

USD 4.27B
TECL Direxion Daily Technology Bull.. 1.17 %

N/A

USD 3.43B
YINN Direxion Daily FTSE China Bull.. 1.02 %

N/A

USD 1.61B
USD ProShares Ultra Semiconductors 0.95 %

N/A

USD 1.16B
UDOW ProShares UltraPro Dow30 0.95 %

N/A

USD 0.91B
LABU Direxion Daily S&P Biotech Bul.. 1.14 %

N/A

USD 0.82B

ETFs Containing XPP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Trading--Leveraged Equity) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.05% 73% C 90% A-
Dividend Return 3.96% 95% A 57% F
Total Return 43.02% 76% C+ 91% A-
Trailing 12 Months  
Capital Gain 48.56% 75% C 93% A
Dividend Return 4.23% 95% A 59% D-
Total Return 52.80% 81% B- 94% A
Trailing 5 Years  
Capital Gain -71.56% 18% F 5% F
Dividend Return 1.40% 29% F 4% F
Total Return -70.16% 18% F 4% F
Average Annual (5 Year Horizon)  
Capital Gain -21.71% 1% F 2% F
Dividend Return -21.14% 1% F 2% F
Total Return 0.57% 45% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 34.64% 94% A 30% F
Risk Adjusted Return -61.02% 1% F 3% F
Market Capitalization 0.04B 12% F 10% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.